- Home
- APLS vs SUPN Comparison
APLS vs SUPN Comparison
Compare APLS & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLS
- SUPN
- Stock Information
- Founded
- APLS 2009
- SUPN 2005
- Country
- APLS United States
- SUPN United States
- Employees
- APLS N/A
- SUPN N/A
- Industry
- APLS Biotechnology: Pharmaceutical Preparations
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- APLS Health Care
- SUPN Health Care
- Exchange
- APLS Nasdaq
- SUPN Nasdaq
- Market Cap
- APLS 2.2B
- SUPN 1.9B
- IPO Year
- APLS 2017
- SUPN 2012
- Fundamental
- Price
- APLS $19.00
- SUPN $33.56
- Analyst Decision
- APLS Buy
- SUPN Hold
- Analyst Count
- APLS 19
- SUPN 2
- Target Price
- APLS $37.89
- SUPN $36.00
- AVG Volume (30 Days)
- APLS 2.2M
- SUPN 681.6K
- Earning Date
- APLS 07-31-2025
- SUPN 08-05-2025
- Dividend Yield
- APLS N/A
- SUPN N/A
- EPS Growth
- APLS N/A
- SUPN N/A
- EPS
- APLS N/A
- SUPN 1.11
- Revenue
- APLS $775,839,000.00
- SUPN $667,997,000.00
- Revenue This Year
- APLS $10.84
- SUPN N/A
- Revenue Next Year
- APLS $10.51
- SUPN $15.74
- P/E Ratio
- APLS N/A
- SUPN $30.78
- Revenue Growth
- APLS 48.04
- SUPN 11.82
- 52 Week Low
- APLS $16.10
- SUPN $27.05
- 52 Week High
- APLS $41.94
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- APLS 49.48
- SUPN 57.11
- Support Level
- APLS $18.48
- SUPN $32.94
- Resistance Level
- APLS $20.40
- SUPN $34.21
- Average True Range (ATR)
- APLS 0.99
- SUPN 1.06
- MACD
- APLS -0.09
- SUPN 0.04
- Stochastic Oscillator
- APLS 24.47
- SUPN 56.90
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.